News
Stem Cell Therapy for Stroke & Dementia - Dr. S. Thomas Carmichael
A one-time injection of an experimental stem cell therapy can repair brain damage and improve memory function in mice with conditions that replicate human strokes and dementia, a new UCLA study finds.
UCLA forms collaboration with Yuyu Pharma to develop drug for stroke recovery
UCLA forms collaboration with Yuyu Pharma to develop drug for stroke recovery
UCLA has formed a research collaboration with South Korea-based Yuyu Pharma to develop drugs that could help people recover after a stroke.
Yuyu will develop drug candidates and UCLA researchers will conduct preclinical trials that could lead to further development of new compounds.
Pearl Cohen Poster Award Competition for LABEST 2022
*** THE POSTER COMPETITION IS NOW CLOSED***
The Pearl Cohen Poster Award Competition ($250 - $750 cash prizes) is a unique opportunity to showcase your bioscience research programs in front of pharma and biotech industry leaders. All accepted submissions will be displayed during digital “Poster Plaza Session”, arranged by therapeutic area, with three presentation timeslots (complimentary admission included for the lead author). Award winners will be announced during the event.
Academia Meets the Market Parts 1&2
In the two part series "Academia Meets The Market", In Vivo's William Looney interviews Amir Naiberg, associate vice chancellor and CEO & president of UCLA Technology Development Group to discuss the growth and strategy of tech transfer at UCLA through research, investments, partnerships, and programs.
Leading Universities Launch Joint Technology Licensing Program
Leading Universities Launch Joint Technology Licensing Program
Support the UCLA Innovation Fund with a tax-deductible contribution
UCLA created the Innovation Fund to bridge the gap between early-stage research and translation of life-impacting technology. Support the profound work that our faculty and researchers do right now with a tax-deductible donation.
Avenda Health Receives FDA Clearance for their Focal Laser Ablation System
Avenda Health, a software and medical device company that spun out of UCLA, announced today that the Food and Drug Administration (FDA) has cleared their focal laser ablation system.